Octamoxin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Octamoxin
Accession Number
DB09249
Description

Octamoxin, also known as 2-octylhydrazine, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the hydrazine chemical class. This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued.

Type
Small Molecule
Groups
Withdrawn
Structure
Thumb
Weight
Average: 144.262
Monoisotopic: 144.162648652
Chemical Formula
C8H20N2
Synonyms
  • 2-octylhydrazine

Pharmacology

Indication

For the treatment of depression.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Abciximab.
AcarboseOctamoxin may increase the hypoglycemic activities of Acarbose.
AcebutololOctamoxin may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Octamoxin.
AcemetacinThe risk or severity of hypertension can be increased when Octamoxin is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Octamoxin.
AcetohexamideOctamoxin may increase the hypoglycemic activities of Acetohexamide.
AcetophenazineThe risk or severity of extrapyramidal symptoms can be increased when Acetophenazine is combined with Octamoxin.
Acetylsalicylic acidThe risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Acetylsalicylic acid.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
International/Other Brands
Nimaol / Ximaol

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alkylhydrazines. These are organonitrogen compounds that containing a hydrazine group to which an alkyl group is attached.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Hydrazines and derivatives
Direct Parent
Alkylhydrazines
Alternative Parents
Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Aliphatic acyclic compound / Alkylhydrazine / Hydrocarbon derivative / Organopnictogen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
0HXY3M6S54
CAS number
4684-87-1
InChI Key
FODQIVGFADUBKE-UHFFFAOYSA-N
InChI
InChI=1S/C8H20N2/c1-3-4-5-6-7-8(2)10-9/h8,10H,3-7,9H2,1-2H3
IUPAC Name
(octan-2-yl)hydrazine
SMILES
CCCCCCC(C)NN

References

General References
  1. Gayral L, Stern H, Puyuelo R: [Indications and results of the treatment of mental depression by octamoxine (ximaol)]. Therapie. 1966 Sep-Oct;21(5):1183-90. [PubMed:5976767]
PubChem Compound
20811
PubChem Substance
310265152
ChemSpider
19587
ChEBI
134768
ChEMBL
CHEMBL2104528
Wikipedia
Octamoxin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.27 mg/mLALOGPS
logP2.54ALOGPS
logP2.26ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)5.92ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area38.05 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity56.99 m3·mol-1ChemAxon
Polarizability19.11 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 23, 2015 22:02 / Updated on June 12, 2020 10:52

Pm 3